An Open-label Non-randomised Multicentre Comparative Phase I Studyof the Pharmacokinetics Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients with Advanced Solid Tumours and Normal Renal Function or Renal Impairment

Cancer type: Solide tumores

Phase: I

Principal Investigator: Mau-Sørensen Morten

Country: DK

Keywords: Denmark, Rigshospitalet, olaparib, renal function

Status: Completed

Link to